OBJECTIVES: Measurement of serotonin concentrations in blood is considered to be important for the clinical studies of diseases involving vascular endothelial injury. We have developed a high-performance liquid chromatographic (HPLC) method for measurement of serotonin level in platelet-poor plasma (PPP). METHODS: Venous blood samples were collected using vacuum tubes containing ethylenediaminetetraacetic acid (EDTA) dipotassium salt; the optimum concentration in blood was 7.4 mmol/l. Serotonin in samples was separated by HPLC with a column-switching system, and was specifically converted into a fluorescent derivative with benzylamine for convenient detection. RESULTS: The between-day assay coefficient of variation for a serotonin level (5.1 nmol/l) in PPP was 6.2%. The mean concentration of serotonin in PPP in healthy subjects was 5.7 +/- 3.0 nmol/l. The serotonin levels in PPP in patients with ischemic heart disease were significantly higher than those in healthy subjects (P = 0.001). CONCLUSIONS: The developed method had sufficient performance to determine serotonin levels in PPP from patients with ischemic heart disease.
OBJECTIVES: Measurement of serotonin concentrations in blood is considered to be important for the clinical studies of diseases involving vascular endothelial injury. We have developed a high-performance liquid chromatographic (HPLC) method for measurement of serotonin level in platelet-poor plasma (PPP). METHODS: Venous blood samples were collected using vacuum tubes containing ethylenediaminetetraacetic acid (EDTA) dipotassium salt; the optimum concentration in blood was 7.4 mmol/l. Serotonin in samples was separated by HPLC with a column-switching system, and was specifically converted into a fluorescent derivative with benzylamine for convenient detection. RESULTS: The between-day assay coefficient of variation for a serotonin level (5.1 nmol/l) in PPP was 6.2%. The mean concentration of serotonin in PPP in healthy subjects was 5.7 +/- 3.0 nmol/l. The serotonin levels in PPP in patients with ischemic heart disease were significantly higher than those in healthy subjects (P = 0.001). CONCLUSIONS: The developed method had sufficient performance to determine serotonin levels in PPP from patients with ischemic heart disease.
Authors: Wilhelmina H A de Jong; Marianne H L I Wilkens; Elisabeth G E de Vries; Ido P Kema Journal: Anal Bioanal Chem Date: 2010-02-07 Impact factor: 4.142
Authors: Miguel Bernardes; Tiago Vieira; Raquel Lucas; Jorge Pereira; Lúcia Costa; Francisco Simões-Ventura; Maria João Martins Journal: Rheumatol Int Date: 2017-10-09 Impact factor: 2.631
Authors: Trond Brattelid; Eirik Qvigstad; Lise R Moltzau; Silje V S Bekkevold; Dagny L Sandnes; Jon Arne K Birkeland; Tor Skomedal; Jan-Bjørn Osnes; Ivar Sjaastad; Finn Olav Levy Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240